NHS Leeds, based at HMP Leeds, Armley, Leeds.
Br J Gen Pract. 2011 Dec;61(593):e772-80. doi: 10.3399/bjgp11X613106.
Many opiate users require prescribed medication to help them achieve abstinence, commonly taking the form of a detoxification regime. In UK prisons, drug users are nearly universally treated for their opiate use by primary care clinicians, and once released access GP services where 40% of practices now treat drug users. There is a paucity of evidence evaluating methadone and buprenorphine (the two most commonly prescribed agents in the UK) for opiate detoxification.
To evaluate whether buprenorphine or methadone help to achieve drug abstinence at completion of a reducing regimen for heroin users presenting to UK prison health care for detoxification.
Open-label, pragmatic, randomised controlled trial in three prison primary healthcare departments in the north of England.
Prisoners (n = 306) using illicit opiates were recruited and given daily sublingual buprenorphine or oral methadone, in the context of routine care, over a standard reduced regimen of not more than 20 days. The primary outcome measure was abstinence from illicit opiates at 8 days post detoxification, as indicated by urine test (self-report/clinical notes where urine sample was not feasible). Secondary outcomes were also recorded.
Abstinence was ascertained for 73.7% at 8 days post detoxification (urine sample = 52.6%, self report = 15.2%, clinical notes = 5.9%). There was no statistically significant difference in the odds of achieving abstinence between methadone and buprenorphine (odds ratio [OR] = 1.69; 95% confidence interval [CI] = 0.81 to 3.51; P = 0.163). Abstinence was associated solely with whether or not the participant was still in prison at that time (15.22 times the odds; 95% CI = 4.19 to 55.28). The strongest association for lasting abstinence was abstinence at an earlier time point.
There is equal clinical effectiveness between methadone and buprenorphine in achieving abstinence from opiates at 8 days post detoxification within prison.
许多阿片类药物使用者需要服用规定的药物来帮助他们戒除毒瘾,通常采用戒毒治疗方案的形式。在英国监狱中,初级保健临床医生几乎普遍为吸毒者治疗阿片类药物使用问题,而一旦他们获释,就可以使用全科医生服务,现在有 40%的诊所治疗吸毒者。评估美沙酮和丁丙诺啡(英国最常开的两种戒毒药物)用于阿片类药物戒毒的证据非常有限。
评估丁丙诺啡或美沙酮是否有助于在为寻求英国监狱戒毒治疗的海洛因使用者进行减少剂量治疗方案结束时实现药物戒除。
在英格兰北部的三个监狱初级保健部门进行开放标签、实用、随机对照试验。
招募使用非法阿片类药物的囚犯,并在常规护理的背景下,每天给予舌下丁丙诺啡或口服美沙酮,在不超过 20 天的标准减少剂量治疗方案中。主要结局测量指标是在戒毒后 8 天内通过尿液检测(自我报告/临床记录,在无法进行尿液样本时)判断是否戒除非法阿片类药物。也记录了次要结局。
在戒毒后 8 天,有 73.7%的人确定已经戒除了非法阿片类药物(尿液样本为 52.6%,自我报告为 15.2%,临床记录为 5.9%)。美沙酮和丁丙诺啡在实现戒除的可能性方面没有统计学上的显著差异(比值比[OR] = 1.69;95%置信区间[CI] = 0.81 至 3.51;P = 0.163)。是否仍在监狱中是唯一与是否实现戒除相关的因素(可能性为 15.22 倍;95%CI = 4.19 至 55.28)。持久戒除的最强关联是更早时间点的戒除。
在监狱内,戒毒后 8 天,丁丙诺啡和美沙酮在实现阿片类药物戒除方面具有同等的临床效果。